scholarly journals Increased Volume and Distinct Pattern of Silent Cerebral Infarcts in Healthy, Young Adults with Sickle Cell Trait

Blood ◽  
2017 ◽  
Vol 130 (Suppl_1) ◽  
pp. 757-757
Author(s):  
Andria L Ford ◽  
Melanie E Fields ◽  
Kristin P Guilliams ◽  
Dustin K Ragan ◽  
Chen Yasheng ◽  
...  

Abstract Background: Sickle cell trait (SCT) is common, affecting 7-8% of African Americans. Previously thought to be of little clinical consequence except under conditions of severe hypoxic/metabolic stress, recent studies have shown that SCT is independently associated with chronic vascular diseases including kidney disease, coronary artery disease, overt stroke, and pulmonary embolism. It has been postulated that SCT underlies the increased prevalence of cerebrovascular disease in African-Americans after adjusting for excess risk factors. Prospective imaging studies evaluating the natural history of cerebral ischemia in SCT are lacking; thus, the true disease burden is unknown. In this study, we hypothesized that individuals with SCT are at increased risk of silent cerebral infarctions (SCI) compared to healthy young adults, but with a lower risk of SCIs compared to young adults with sickle cell anemia (SCA). We further evaluated and compared the patterns of SCIs within SCT and SCA. Methods: Three cohorts were prospectively recruited from a tertiary care referral center for pediatric and adult SCA: (1) young adults with SCA, (2) healthy, young adults with SCT, and (3) healthy, age- and race-matched, controls. Control and SCT subjects were excluded for history of hypertension, diabetes, anemia, dyslipidemia, chronic medical or neurological illness, or severe trauma; individuals with SCA were excluded if on chronic transfusion therapy or history of overt stroke, vasculopathy, or chronic neurological illness. Brain MRI T1 and FLAIR maps were evaluated for the presence of two lesion types (defined in Wardlaw et al, Lancet Neurol, 2013): (a) FLAIR lesions were defined as FLAIR hyperintensity > 3mm in diameter; (b) SCIs were defined as FLAIR lesions with the additional requirement of CSF-like hypointensity on T1. Thus, SCIs represented a subset of all FLAIR lesions. FLAIR lesions were outlined by a vascular neurologist using MIPAV (Medical Image Processing, Analysis and Visualization, https://mipav.cit.nih.gov/) from which individual lesion volumes were calculated. Baseline characteristics, prevalence of SCIs, and volume of FLAIR lesions in SCT were compared to controls and SCA (Fishers Exact for categorical variables; Mann-Whitney U for continuous variables). To evaluate the distribution of SCIs in SCT relative to healthy controls and SCA, three lesion density maps were created. Lesions drawn on FLAIR 5mm slice thickness were stretched in the z-direction to 10mm for display of SCI pattern on few slices. Results: Control, SCT, and SCA adults were similar with respect to baseline characteristics, except SCA subjects were younger and fewer female than SCT (Table). Ten (45%) of the SCA subjects were on hydroxyurea. We acquired LDL, glucose, and blood pressure to ensure that SCT participants did not have higher risk of SCIs compared to controls due to ongoing comorbidities (Table). Imaging Outcomes: We found greater FLAIR lesion volumes in SCT than controls (292 vs. 90 mm3, p=0.02) and a trend towards greater prevalence of SCIs -- 5 of 11 (45%) in SCT compared to 1 of 11 (9%) in controls (p=0.15). FLAIR lesion volumes and SCI prevalence were higher in SCA compared to SCT (p=0.01 and p=0.02, respectively). Lesion density maps (Figure) were created to evaluate SCI patterns in SCT and SCA. In the SCA cohort, lesion density was highest within the internal borderzone (where cerebral blood flow is at a nadir), while this region was relatively unaffected in SCT. In contrast, a distinct pattern of small cortical/subcortical strokes distributed in a stochastic pattern (not following any particular vascular territory) were found in both SCT and SCA. Conclusions: We found greater FLAIR lesion volumes and a trend towards a greater prevalence of SCIs in healthy individuals with SCT. We postulate that SCIs found in SCT may represent an etiologic subtype of SCIs found in SCA, representing microembolic events or a microvasculopathy, in contrast to the etiology of internal borderzone infarction which likely represents a heightened ischemic vulnerability within low CBF regions in the setting of chronic, severe anemia. Larger studies are necessary to determine if SCT carries a heightened risk of silent cerebral ischemia, which would impact society at large given the high prevalence of SCT and the known effects of SCIs on cognitive disability. Figure Figure. Disclosures Fields: Proclara Biosciences: Equity Ownership. Hulbert: Pfizer: Other: Spouse employment at Pfizer.

2017 ◽  
Vol 27 (1) ◽  
pp. 11 ◽  
Author(s):  
Nicole D. Dueker ◽  
David Della-Morte ◽  
Tatjana Rundek ◽  
Ralph L. Sacco ◽  
Susan H. Blanton

<p class="Pa7">Sickle cell anemia (SCA) is a common hematological disorder among individu­als of African descent in the United States; the disorder results in the production of abnormal hemoglobin. It is caused by homozygosity for a genetic mutation in HBB; rs334. While the presence of a single mutation (sickle cell trait, SCT) has long been considered a benign trait, recent research suggests that SCT is associated with renal dysfunction, including a decrease in estimated glomerular filtration rate (eGFR) and increased risk of chronic kidney disease (CKD) in African Americans. It is currently unknown whether similar associations are observed in Hispanics. Therefore, our study aimed to determine if SCT is associated with mean eGFR and CKD in a sample of 340 Dominican Hispanics from the Northern Manhattan Study. Using regression analyses, we tested rs334 for association with eGFR and CKD, adjusting for age and sex. eGFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration equa­tion and CKD was defined as eGFR &lt; 60 mL/min/1.73 m2. Within our sample, there were 16 individuals with SCT (SCT carriers). We found that SCT carriers had a mean eGFR that was 12.12 mL/min/1.73m2 lower than non-carriers (P=.002). Additionally, SCT carriers had 2.72 times higher odds of CKD compared with non-carriers (P=.09). Taken together, these novel results show that Hispanics with SCT, as found among African Americans with SCT, may also be at increased risk for kidney disease.</p><p class="Pa7"><em>Ethn Dis. </em>2017; 27(1)<strong>:</strong>11-14; doi:10.18865/ed.27.1.11.</p><p class="Pa7"> </p>


2018 ◽  
Vol 5 (1) ◽  
pp. 35
Author(s):  
Titilope Olanipekun ◽  
Valery Effoe ◽  
Ganiat Adeogun ◽  
Agniezka Gaertig ◽  
Myrtle White ◽  
...  

Exertional rhabdomyolysis from sickle cell trait has been documented. Also, cases of rhabdomyolysis from the use of weight loss supplements in the setting of sickle cell trait and exertion have been described. However, the role of sickle cell trait in non-exertional rhabdomyolysis is not clear. We present a case of severe non-exertional rhabdomyolysis from weight loss supplement in a patient with sickle cell trait.A 45-year-old African American female with sickle cell trait presented to the emergency department with two days history of fatigue and mild breathlessness. She also reported diarrhea and vomiting for five days before presentation. She admitted to taking Garcinia cambogia (a dietary supplement) for weight loss one week prior to the onset of symptoms. She denied alcohol or drug use, rigorous physical activity or trauma.She was dehydrated on examination. Laboratory values revealed markedly elevated serum creatine phosphokinase (CPK) and creatinine levels. Garcinia cambogia was discontinued and she was hydrated with intravenous fluids. Her CPK and creatinine levels significantly trended down and she was discharged home with no apparent sequelae.Our patient had multiple episodes of diarrhea and vomiting likely from the use of Garcinia cambogia. We believe she suffered non-exertional rhabdomyolysis from dehydration in the setting of sickle cell trait. Though dietary weight loss supplements are marketed as generally safe, this case suggests otherwise. We emphasize that clinicians routinely inquire about use of these supplements and provide appropriate counseling to patients on the adverse effects, especially among those with sickle cell trait.


Author(s):  
Janhavi Mahajan ◽  
Dhruv Talwar ◽  
Sunil Kumar ◽  
Sourya Acharya ◽  
Yogesh Kakde

ECAST Or exercise collapse associated with sickle cell trait is a rare phenomenon associated with sickle cell trait and is an important presentation of sickle cell disease in sports medicine. Collapse is seen following vigorous physical activity, which is due to excessive heat, dehydration and other factors associated with physical exercise. This rare syndrome is often missed by the treating physicians as a result of a lack of knowledge about this rare entity leading to massive underreporting. It is important to identify ECAST as a cause of the collapse in young athletes to prevent mortality and morbidity and in order to provide prompt treatment. We report a case of a 25- year-old young male who was a bodybuilder and reported to the gym after a one-year-long break due to lockdown restrictions of COVID19. After a vigorous exercise session, he collapsed in the gym and was brought to the emergency department. After proper history taking and examination, he was suspected to be a case of ECAST due to a history of a similar episode three years back which was treated as a case of exertional syncope with intravenous fluid therapy and a family history of Sickle cell trait with his mother and father both having sickle cell AS Pattern. Ultimately our patient turned out to be a case of Sickle Cell Trait with evidence of AS pattern on Hb electrophoresis and a small-sized spleen visualized on CT Scan of the abdomen. The patient was managed successfully with intravenous fluids and blood transfusion and was discharged in a stable condition. He was counseled about moderating his exercise and is doing well on follow-up.


Circulation ◽  
2017 ◽  
Vol 135 (suppl_1) ◽  
Author(s):  
Mary E Lacy ◽  
Gregory A Wellenius ◽  
Adolfo Correa ◽  
Mercedes R Carnethon ◽  
Robert I Leim ◽  
...  

Introduction: Existing models to predict incident diabetes mellitus (DM) perform better in Whites than African Americans. In models that incorporate hemoglobin A1c (A1C) as a predictor of DM, the difference in model performance by race is more pronounced. In a recent study, we found that A1C was systematically underestimating glycemia in African Americans with sickle cell trait (SCT). Hypothesis: Given the poorer performance of DM prediction models in African Americans than Whites and the impact of SCT on the A1C-glycemia association, we hypothesized that incorporating sickle cell trait into DM prediction models would improve the ability of the model to predict future risk of DM. Methods: We pooled data collected from 2000-2012 on 3,122 African Americans (8.6% with SCT) from the Jackson Heart Study (JHS; n=2,065; mean age=54.71 years) and CARDIA (n=1,057; mean age=44.53). Over 5 years of follow-up in CARDIA and 10 years of follow-up in JHS, 85 CARDIA participants (8.1%) and 342 JHS participants (16.6%) developed DM. Using generalized estimating equations to account for correlation of repeated measures, we compared the discriminative ability and net reclassification improvement (NRI) resulting from the addition of SCT for a series of prediction models. Results: Overall, the addition of SCT to prediction models did not result in significant improvement in the discriminative ability. However, by the NRI index, the addition of SCT to measures of glycemia and to a fuller risk prediction model did improve prediction of DM. In the full model, adding SCT*A1C as a predictor resulted in 2% of events being reclassified as higher risk and 45% of non-events being reclassified as lower risk. Conclusion: Our results suggest that incorporating SCT into DM prediction for African Americans may result in modest improvement in model performance.


Author(s):  
Dalal S. Aldossary ◽  
Vandy Black ◽  
Miriam O. Ezenwa ◽  
Agatha M. Gallo ◽  
Versie M. Johnson‐Mallard ◽  
...  

2019 ◽  
Vol 11 ◽  
pp. 27-33 ◽  
Author(s):  
Christina R. Cahill ◽  
Justin M. Leach ◽  
Leslie A. McClure ◽  
Marguerite Ryan Irvin ◽  
Neil A. Zakai ◽  
...  

2017 ◽  
Vol 23 (7) ◽  
pp. 813-829 ◽  
Author(s):  
Tilicia L. Mayo-Gamble ◽  
Priscilla A. Barnes ◽  
Jennifer Cunningham Erves ◽  
Susan E. Middlestadt ◽  
Hsien-Chang Lin

2018 ◽  
Vol 75 (7) ◽  
pp. 802 ◽  
Author(s):  
Hyacinth I. Hyacinth ◽  
Cara L. Carty ◽  
Samantha R. Seals ◽  
Marguerite R. Irvin ◽  
Rakhi P. Naik ◽  
...  

Author(s):  
Alexandra Szabova ◽  
Kenneth R Goldschneider

0.2% of African-Americans have sickle cell anemia while, with 8% to 10% have sickle cell trait. This chapter provides an overiew of the etiology, pathophysiology, and treatment of sickle cell anemia as they affect anesthetic management—before, during, and after surgery.


Sign in / Sign up

Export Citation Format

Share Document